Correlation Between Citigroup and Plus Therapeutics

Can any of the company-specific risk be diversified away by investing in both Citigroup and Plus Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Citigroup and Plus Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Citigroup and Plus Therapeutics, you can compare the effects of market volatilities on Citigroup and Plus Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Citigroup with a short position of Plus Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Citigroup and Plus Therapeutics.

Diversification Opportunities for Citigroup and Plus Therapeutics

-0.52

Correlation Coefficient

Citigroup  Plus Therapeutics

Excellent diversification

The 3 months correlation between Citigroup and Plus is -0.52. Overlapping area represents the amount of risk that can be diversified away by holding Citigroup and Plus Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Plus Therapeutics and Citigroup is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Citigroup are associated (or correlated) with Plus Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Plus Therapeutics has no effect on the direction of Citigroup i.e., Citigroup and Plus Therapeutics go up and down completely randomly.

Pair Corralation between Citigroup and Plus Therapeutics

Taking into account the 90-day investment horizon Citigroup is expected to generate 0.24 times more return on investment than Plus Therapeutics. However, Citigroup is 4.1 times less risky than Plus Therapeutics. It trades about 0.1 of its potential returns per unit of risk. Plus Therapeutics is currently generating about 0.02 per unit of risk. If you would invest  4,460  in Citigroup on September 12, 2024 and sell it today you would earn a total of  2,790  from holding Citigroup or generate 62.56% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Citigroup  vs.  Plus Therapeutics

Citigroup

Risk-Adjusted Performance

16 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Citigroup are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating fundamental indicators, Citigroup exhibited solid returns over the last few months and may actually be approaching a breakup point.

Plus Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Plus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Plus Therapeutics is not utilizing all of its potentials. The current stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Pair Trading with Citigroup and Plus Therapeutics

The main advantage of trading using opposite Citigroup and Plus Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Citigroup position performs unexpectedly, Plus Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Plus Therapeutics will offset losses from the drop in Plus Therapeutics' long position.

The idea behind Citigroup and Plus Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.